Wilbur H. Gantz

This profile gathers the share dealings of Wilbur H. Gantz across 3 companies, led by W.W. Grainger, Inc., Aptinyx Inc. and Aevi Genomic Medicine, LLC. We count 57 filings; the first trade dates from 20 March 2007 and the latest from 25 June 2018.

Market trades split into 4 purchases (€439k) and 37 sales (€1.1M). Taken together, the sales exceed the purchases by €618k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant and 7 option exercises. Since January 2018: 2 purchases and no sales on the market.

A typical purchase (the median) is worth €82k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 26 June 2018: an open-market purchase of €83k, in Aptinyx Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.